Lucy Hwa-Yue Young, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Choroid Neoplasms | 9 | 2013 | 177 | 1.940 |
Why?
|
| Toxoplasmosis, Ocular | 7 | 2017 | 29 | 1.610 |
Why?
|
| Eye Foreign Bodies | 4 | 2024 | 49 | 1.540 |
Why?
|
| Laser Coagulation | 5 | 2016 | 329 | 1.400 |
Why?
|
| Vitrectomy | 8 | 2019 | 391 | 1.270 |
Why?
|
| Toxoplasma | 7 | 2019 | 151 | 1.130 |
Why?
|
| Eye Diseases | 4 | 2024 | 651 | 1.090 |
Why?
|
| Angiogenesis Inhibitors | 6 | 2022 | 2047 | 1.070 |
Why?
|
| Endophthalmitis | 4 | 2014 | 257 | 0.950 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 4 | 2016 | 24 | 0.920 |
Why?
|
| Macular Degeneration | 8 | 2022 | 1001 | 0.880 |
Why?
|
| Siderosis | 1 | 2024 | 103 | 0.830 |
Why?
|
| Macular Edema | 2 | 2017 | 374 | 0.780 |
Why?
|
| Vitreous Body | 5 | 2016 | 399 | 0.750 |
Why?
|
| Retinitis | 2 | 2015 | 36 | 0.750 |
Why?
|
| Melanoma, Experimental | 5 | 2004 | 559 | 0.730 |
Why?
|
| Diabetic Retinopathy | 3 | 2017 | 1267 | 0.720 |
Why?
|
| Intravitreal Injections | 4 | 2022 | 384 | 0.670 |
Why?
|
| Eye Infections, Viral | 4 | 2016 | 60 | 0.660 |
Why?
|
| Retinal Diseases | 5 | 2018 | 702 | 0.650 |
Why?
|
| Ophthalmia, Sympathetic | 2 | 2011 | 18 | 0.640 |
Why?
|
| Cytomegalovirus Retinitis | 2 | 2011 | 56 | 0.620 |
Why?
|
| Retinal Detachment | 6 | 2016 | 428 | 0.590 |
Why?
|
| Scleral Buckling | 2 | 2016 | 95 | 0.590 |
Why?
|
| Blood Volume | 3 | 2004 | 550 | 0.590 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2022 | 3480 | 0.580 |
Why?
|
| Eye Infections, Bacterial | 2 | 2014 | 239 | 0.580 |
Why?
|
| Lasers, Semiconductor | 1 | 2016 | 41 | 0.520 |
Why?
|
| Antiparasitic Agents | 1 | 2015 | 43 | 0.480 |
Why?
|
| Toxoplasmosis | 3 | 2019 | 93 | 0.460 |
Why?
|
| Antiviral Agents | 5 | 2016 | 3056 | 0.440 |
Why?
|
| Osteoma | 1 | 2013 | 12 | 0.430 |
Why?
|
| Antiprotozoal Agents | 2 | 2011 | 94 | 0.420 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2014 | 190 | 0.410 |
Why?
|
| Uveitis, Posterior | 3 | 2010 | 45 | 0.410 |
Why?
|
| Wet Macular Degeneration | 1 | 2015 | 162 | 0.410 |
Why?
|
| Mucolipidoses | 1 | 2012 | 82 | 0.400 |
Why?
|
| Poisoning | 1 | 2013 | 252 | 0.380 |
Why?
|
| Retinal Perforations | 3 | 2019 | 138 | 0.380 |
Why?
|
| Sulfadiazine | 1 | 2010 | 18 | 0.370 |
Why?
|
| Aspergillus niger | 1 | 2010 | 18 | 0.370 |
Why?
|
| Iron Overload | 1 | 2013 | 240 | 0.360 |
Why?
|
| Cataract Extraction | 1 | 2014 | 465 | 0.350 |
Why?
|
| Eye Injuries | 4 | 2016 | 227 | 0.340 |
Why?
|
| Vision Disorders | 4 | 2018 | 1084 | 0.340 |
Why?
|
| Steroids | 1 | 2015 | 926 | 0.340 |
Why?
|
| Visual Acuity | 12 | 2021 | 2642 | 0.330 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 662 | 0.320 |
Why?
|
| Aspergillosis | 1 | 2010 | 243 | 0.320 |
Why?
|
| Eye Diseases, Hereditary | 2 | 2020 | 118 | 0.310 |
Why?
|
| Blindness | 1 | 2012 | 582 | 0.310 |
Why?
|
| Chemoprevention | 1 | 2011 | 326 | 0.310 |
Why?
|
| Retinal Pigment Epithelium | 3 | 2017 | 301 | 0.300 |
Why?
|
| Phacoemulsification | 1 | 2010 | 149 | 0.300 |
Why?
|
| Cataract | 2 | 2014 | 827 | 0.300 |
Why?
|
| Retina | 4 | 2019 | 2637 | 0.300 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 1870 | 0.300 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2015 | 1793 | 0.290 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2006 | 250 | 0.270 |
Why?
|
| Eye Infections | 1 | 2007 | 62 | 0.270 |
Why?
|
| Coccidiostats | 1 | 2006 | 3 | 0.270 |
Why?
|
| Onchocerciasis, Ocular | 1 | 2006 | 7 | 0.270 |
Why?
|
| Toxocariasis | 1 | 2006 | 12 | 0.270 |
Why?
|
| Hyperthermia, Induced | 3 | 2004 | 416 | 0.260 |
Why?
|
| Eye Infections, Parasitic | 1 | 2006 | 25 | 0.260 |
Why?
|
| Corneal Diseases | 2 | 2022 | 536 | 0.260 |
Why?
|
| Cysticercosis | 1 | 2006 | 35 | 0.260 |
Why?
|
| Triamcinolone Acetonide | 1 | 2006 | 100 | 0.250 |
Why?
|
| Uveomeningoencephalitic Syndrome | 1 | 2005 | 22 | 0.250 |
Why?
|
| Microphthalmos | 1 | 2005 | 58 | 0.250 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2796 | 0.250 |
Why?
|
| Choroid Diseases | 1 | 2005 | 63 | 0.240 |
Why?
|
| Chorioretinitis | 3 | 2015 | 43 | 0.240 |
Why?
|
| Herpes Zoster Ophthalmicus | 2 | 2016 | 37 | 0.240 |
Why?
|
| Dwarfism | 1 | 2005 | 137 | 0.240 |
Why?
|
| Sturge-Weber Syndrome | 1 | 2005 | 85 | 0.230 |
Why?
|
| Hydroxychloroquine | 2 | 2018 | 426 | 0.230 |
Why?
|
| Oxides | 2 | 2004 | 401 | 0.230 |
Why?
|
| Glaucoma | 2 | 2022 | 1182 | 0.230 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 2197 | 0.220 |
Why?
|
| Epiretinal Membrane | 2 | 2019 | 73 | 0.220 |
Why?
|
| Protozoan Proteins | 2 | 2019 | 839 | 0.220 |
Why?
|
| Drug Implants | 1 | 2004 | 230 | 0.220 |
Why?
|
| Retinal Degeneration | 1 | 2007 | 412 | 0.220 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 981 | 0.210 |
Why?
|
| Bone Marrow Transplantation | 1 | 2011 | 2693 | 0.210 |
Why?
|
| Glucocorticoids | 4 | 2010 | 2144 | 0.210 |
Why?
|
| Syphilis | 1 | 2005 | 243 | 0.210 |
Why?
|
| Antibodies, Protozoan | 2 | 2015 | 251 | 0.200 |
Why?
|
| Fundus Oculi | 3 | 2018 | 541 | 0.200 |
Why?
|
| Humans | 66 | 2024 | 758381 | 0.190 |
Why?
|
| Retinal Dystrophies | 2 | 2020 | 64 | 0.190 |
Why?
|
| Contusions | 1 | 2002 | 79 | 0.190 |
Why?
|
| Ophthalmology | 3 | 2018 | 549 | 0.190 |
Why?
|
| Rabbits | 6 | 2006 | 4771 | 0.190 |
Why?
|
| Myasthenia Gravis | 1 | 2024 | 212 | 0.190 |
Why?
|
| Anterior Eye Segment | 1 | 2002 | 141 | 0.180 |
Why?
|
| Myositis | 1 | 2024 | 269 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 5629 | 0.180 |
Why?
|
| Laser Therapy | 3 | 2010 | 1089 | 0.180 |
Why?
|
| Hemangioma | 1 | 2005 | 727 | 0.180 |
Why?
|
| Photochemotherapy | 4 | 2017 | 819 | 0.170 |
Why?
|
| Delayed-Action Preparations | 1 | 2004 | 961 | 0.170 |
Why?
|
| Organometallic Compounds | 1 | 2003 | 648 | 0.170 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2019 | 44 | 0.170 |
Why?
|
| Serotyping | 1 | 2019 | 324 | 0.160 |
Why?
|
| Endotamponade | 1 | 2019 | 37 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2011 | 2244 | 0.160 |
Why?
|
| Susac Syndrome | 1 | 2018 | 22 | 0.160 |
Why?
|
| Fluorescein Angiography | 5 | 2018 | 1044 | 0.160 |
Why?
|
| Tomography, Optical Coherence | 6 | 2019 | 2880 | 0.150 |
Why?
|
| Electroretinography | 3 | 2020 | 517 | 0.150 |
Why?
|
| Complement Factor B | 1 | 2017 | 72 | 0.150 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 3024 | 0.150 |
Why?
|
| Protein Array Analysis | 1 | 2019 | 401 | 0.150 |
Why?
|
| Phosphotransferases (Phosphate Group Acceptor) | 1 | 2017 | 18 | 0.150 |
Why?
|
| Ribonucleosides | 1 | 2017 | 79 | 0.150 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2017 | 85 | 0.150 |
Why?
|
| Iron | 2 | 2004 | 1786 | 0.140 |
Why?
|
| Cannabinoids | 1 | 2019 | 172 | 0.140 |
Why?
|
| Cornea | 2 | 2022 | 1326 | 0.140 |
Why?
|
| Foscarnet | 1 | 2016 | 35 | 0.140 |
Why?
|
| Receptor, TIE-2 | 1 | 2017 | 176 | 0.130 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2022 | 666 | 0.130 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2018 | 2159 | 0.130 |
Why?
|
| Retinal Drusen | 1 | 2016 | 74 | 0.130 |
Why?
|
| Cytosine | 1 | 2016 | 210 | 0.120 |
Why?
|
| rho-Associated Kinases | 1 | 2017 | 280 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2020 | 1074 | 0.120 |
Why?
|
| Diagnosis, Differential | 5 | 2018 | 12951 | 0.120 |
Why?
|
| Pseudophakia | 1 | 2014 | 60 | 0.120 |
Why?
|
| Uveitis | 2 | 2015 | 393 | 0.120 |
Why?
|
| Photosensitizing Agents | 2 | 2017 | 618 | 0.110 |
Why?
|
| Cannabis | 1 | 2019 | 436 | 0.110 |
Why?
|
| Aptamers, Nucleotide | 1 | 2014 | 163 | 0.110 |
Why?
|
| Artifacts | 1 | 2002 | 1897 | 0.110 |
Why?
|
| Herpes Simplex | 1 | 2016 | 478 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2022 | 3734 | 0.110 |
Why?
|
| Immunomodulation | 1 | 2017 | 545 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2011 | 5649 | 0.100 |
Why?
|
| Eye Abnormalities | 1 | 2015 | 241 | 0.100 |
Why?
|
| Integrins | 1 | 2017 | 836 | 0.100 |
Why?
|
| Ferrosoferric Oxide | 2 | 2004 | 348 | 0.100 |
Why?
|
| Choroid | 2 | 2006 | 350 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2012 | 256 | 0.100 |
Why?
|
| Acyclovir | 1 | 2012 | 268 | 0.100 |
Why?
|
| Host-Parasite Interactions | 1 | 2013 | 301 | 0.100 |
Why?
|
| Disease Progression | 3 | 2014 | 13468 | 0.090 |
Why?
|
| Light | 1 | 2017 | 1345 | 0.090 |
Why?
|
| Drug Administration Routes | 1 | 2011 | 150 | 0.090 |
Why?
|
| Valine | 1 | 2012 | 408 | 0.090 |
Why?
|
| NF-kappa B | 1 | 2019 | 2472 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2017 | 1120 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2012 | 346 | 0.090 |
Why?
|
| Optic Disk | 1 | 2015 | 421 | 0.090 |
Why?
|
| DNA, Protozoan | 1 | 2011 | 228 | 0.090 |
Why?
|
| Ultrasonography | 3 | 2013 | 5952 | 0.090 |
Why?
|
| Integrases | 1 | 2012 | 516 | 0.080 |
Why?
|
| Medicine | 2 | 2014 | 942 | 0.080 |
Why?
|
| Dehydration | 1 | 2010 | 216 | 0.080 |
Why?
|
| Autophagy | 1 | 2017 | 1322 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 8530 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 3 | 2016 | 6068 | 0.080 |
Why?
|
| Urinalysis | 1 | 2010 | 368 | 0.080 |
Why?
|
| Herpesviridae Infections | 1 | 2010 | 270 | 0.080 |
Why?
|
| Peptides | 1 | 2019 | 4341 | 0.070 |
Why?
|
| Melanoma | 1 | 2006 | 5691 | 0.070 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2007 | 38 | 0.070 |
Why?
|
| Immunoglobulin G | 2 | 2017 | 4540 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 6293 | 0.070 |
Why?
|
| Neurons, Efferent | 1 | 2007 | 81 | 0.070 |
Why?
|
| Female | 24 | 2020 | 390316 | 0.070 |
Why?
|
| Animals | 14 | 2017 | 167777 | 0.070 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2006 | 57 | 0.070 |
Why?
|
| Contrast Media | 3 | 2004 | 5298 | 0.070 |
Why?
|
| Penicillin G Benzathine | 1 | 2005 | 25 | 0.060 |
Why?
|
| Eye Enucleation | 1 | 2005 | 128 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 4342 | 0.060 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2005 | 37 | 0.060 |
Why?
|
| Hearing Loss, Noise-Induced | 1 | 2007 | 144 | 0.060 |
Why?
|
| Prostheses and Implants | 2 | 2022 | 1270 | 0.060 |
Why?
|
| Rupture | 2 | 2006 | 443 | 0.060 |
Why?
|
| Risk Factors | 6 | 2016 | 73806 | 0.060 |
Why?
|
| Prognosis | 5 | 2018 | 29558 | 0.060 |
Why?
|
| Incidence | 2 | 2014 | 21273 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 7377 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 1895 | 0.060 |
Why?
|
| Complement Inactivating Agents | 1 | 2024 | 53 | 0.060 |
Why?
|
| Treatment Outcome | 7 | 2016 | 64379 | 0.060 |
Why?
|
| Granuloma | 1 | 2006 | 327 | 0.060 |
Why?
|
| Ganciclovir | 1 | 2004 | 252 | 0.050 |
Why?
|
| Injections | 1 | 2006 | 830 | 0.050 |
Why?
|
| Choroidal Neovascularization | 1 | 2006 | 357 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2013 | 3208 | 0.050 |
Why?
|
| Retrospective Studies | 11 | 2022 | 80170 | 0.050 |
Why?
|
| Immunosuppressive Agents | 2 | 2005 | 4158 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 4284 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 7403 | 0.050 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2005 | 353 | 0.050 |
Why?
|
| Adult | 14 | 2020 | 219916 | 0.050 |
Why?
|
| Middle Aged | 14 | 2024 | 219560 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2004 | 777 | 0.050 |
Why?
|
| Ciliary Body | 1 | 2021 | 166 | 0.050 |
Why?
|
| Optic Nerve Injuries | 1 | 2002 | 147 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 36285 | 0.040 |
Why?
|
| Cochlea | 1 | 2007 | 844 | 0.040 |
Why?
|
| Leber Congenital Amaurosis | 1 | 2020 | 36 | 0.040 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 39060 | 0.040 |
Why?
|
| Body Temperature | 1 | 2003 | 777 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 10171 | 0.040 |
Why?
|
| Young Adult | 6 | 2018 | 58808 | 0.040 |
Why?
|
| Genotype | 3 | 2020 | 12945 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 2013 | 0.040 |
Why?
|
| Prednisone | 1 | 2024 | 1565 | 0.040 |
Why?
|
| DNA | 1 | 2013 | 7199 | 0.040 |
Why?
|
| Macrophages | 1 | 2013 | 5737 | 0.040 |
Why?
|
| Genome, Protozoan | 1 | 2019 | 148 | 0.040 |
Why?
|
| Gadolinium | 1 | 2003 | 959 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2019 | 23341 | 0.040 |
Why?
|
| Tubercidin | 1 | 2017 | 15 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2010 | 1926 | 0.040 |
Why?
|
| Male | 15 | 2024 | 358742 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 117 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 10146 | 0.040 |
Why?
|
| Prosthesis Implantation | 1 | 2022 | 590 | 0.040 |
Why?
|
| Dipyridamole | 1 | 2017 | 141 | 0.040 |
Why?
|
| Brachytherapy | 1 | 2005 | 1236 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 9160 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 6127 | 0.040 |
Why?
|
| Models, Animal | 1 | 2004 | 2112 | 0.040 |
Why?
|
| Metals | 1 | 2002 | 717 | 0.040 |
Why?
|
| Antibodies, Helminth | 1 | 2017 | 57 | 0.040 |
Why?
|
| Vertigo | 1 | 2018 | 202 | 0.040 |
Why?
|
| Retinitis Pigmentosa | 1 | 2020 | 397 | 0.030 |
Why?
|
| HEK293 Cells | 2 | 2017 | 4258 | 0.030 |
Why?
|
| Hallucinogens | 1 | 2019 | 194 | 0.030 |
Why?
|
| Tinnitus | 1 | 2018 | 194 | 0.030 |
Why?
|
| Adolescent | 7 | 2020 | 87888 | 0.030 |
Why?
|
| Complement Activation | 1 | 2017 | 446 | 0.030 |
Why?
|
| Alleles | 2 | 2020 | 6895 | 0.030 |
Why?
|
| Herpesvirus 3, Human | 1 | 2016 | 158 | 0.030 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2002 | 793 | 0.030 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 58681 | 0.030 |
Why?
|
| Acute Disease | 1 | 2006 | 7225 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2019 | 22031 | 0.030 |
Why?
|
| Epitopes | 1 | 2019 | 2502 | 0.030 |
Why?
|
| Simplexvirus | 1 | 2016 | 803 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 14641 | 0.030 |
Why?
|
| Rheumatic Diseases | 1 | 2018 | 639 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 26951 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 4106 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2016 | 2210 | 0.020 |
Why?
|
| Cell Death | 1 | 2017 | 1667 | 0.020 |
Why?
|
| Hearing Loss | 1 | 2018 | 780 | 0.020 |
Why?
|
| Aged | 7 | 2019 | 168217 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2020 | 2564 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 1444 | 0.020 |
Why?
|
| Binding Sites | 1 | 2019 | 6036 | 0.020 |
Why?
|
| Multigene Family | 1 | 2013 | 1076 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2013 | 1743 | 0.020 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2012 | 203 | 0.020 |
Why?
|
| Oxidoreductases | 1 | 2012 | 412 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 20500 | 0.020 |
Why?
|
| Phenotype | 2 | 2020 | 16534 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 1807 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2012 | 2557 | 0.020 |
Why?
|
| Antirheumatic Agents | 1 | 2018 | 1368 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3801 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2017 | 2433 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 1878 | 0.020 |
Why?
|
| Neoplasms | 1 | 2017 | 22030 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2019 | 13447 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 39873 | 0.020 |
Why?
|
| Body Weight | 1 | 2018 | 4603 | 0.020 |
Why?
|
| Mice | 5 | 2017 | 81107 | 0.020 |
Why?
|
| Protein Binding | 1 | 2019 | 9312 | 0.020 |
Why?
|
| Atrophy | 1 | 2012 | 1627 | 0.020 |
Why?
|
| Child | 4 | 2020 | 79813 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 2895 | 0.020 |
Why?
|
| Gene Expression | 1 | 2019 | 7583 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 10747 | 0.020 |
Why?
|
| Parasympathetic Nervous System | 1 | 2007 | 141 | 0.020 |
Why?
|
| Olivary Nucleus | 1 | 2007 | 128 | 0.020 |
Why?
|
| Inflammation | 1 | 2006 | 10719 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 5490 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 3612 | 0.020 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2007 | 253 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 9273 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 11894 | 0.020 |
Why?
|
| Noise | 1 | 2007 | 280 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 1751 | 0.010 |
Why?
|
| Cell Line | 1 | 2017 | 15594 | 0.010 |
Why?
|
| beta-Thalassemia | 1 | 2006 | 235 | 0.010 |
Why?
|
| Logistic Models | 1 | 2018 | 13276 | 0.010 |
Why?
|
| Microglia | 1 | 2012 | 1349 | 0.010 |
Why?
|
| Calcium Channels | 1 | 2007 | 618 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2018 | 4641 | 0.010 |
Why?
|
| United States | 1 | 2011 | 72140 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 13591 | 0.010 |
Why?
|
| DNA Primers | 1 | 2007 | 2816 | 0.010 |
Why?
|
| Cytokines | 1 | 2017 | 7338 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 3705 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2013 | 22006 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2018 | 12876 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2016 | 3401 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 9575 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4567 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 9518 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 15225 | 0.010 |
Why?
|
| Axons | 1 | 2007 | 1674 | 0.010 |
Why?
|
| Aspirin | 1 | 2010 | 3132 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2013 | 18942 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 9405 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2017 | 12096 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2020 | 41252 | 0.010 |
Why?
|
| Mutation | 1 | 2020 | 29915 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 25953 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 29742 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 11070 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 18125 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2016 | 54136 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2006 | 42058 | 0.000 |
Why?
|